|Bid||13.10 x 1100|
|Ask||15.71 x 1400|
|Day's Range||14.59 - 14.92|
|52 Week Range||8.82 - 21.11|
|Beta (5Y Monthly)||0.02|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.22|
BUFFALO, N.Y., Feb. 06, 2020 -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel.
Today, Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex, Inc. (ATNX), informed shareholders he received a notice of a proposed administrative fine of RMB 100,000 (approximately $14,300) from the China Securities Regulatory Commission (“CSRC”), for a matter unrelated to Athenex. The CSRC notice was issued in connection with accounting and compliance infractions by certain senior leaders of Porton Pharma Solutions Ltd (300363.SHE) (“Porton”), a company for which Dr. Lau formerly served as an outside director from March 2016 to December 2019. The infractions, which occurred in 2018, resulted in inaccurate financial disclosures by Porton that were reviewed and approved by its board of directors.
Athenex, Inc. (ATNX) is looking like an interesting pick from a technical perspective, as the company is seeing favorable trends on the moving average crossover front.
The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking...
Sealing Devices has a new location in Colorado Springs. Athenex is ready to inhabit its massive Dunkirk facility. Servotronics increased headcount by 25 percent last year.
Insider buying can be an encouraging signal for potential investors. An executive at a health insurance giant bucked a selling trend. Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit.
Last year's fourth quarter was a rough one for investors and many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing […]
The agreement covers China, Hong Kong and Macao (the “Territory”) and represents an expansion of the existing relationship between the two companies. Athenex will receive payments of up to $200 million which include an upfront, development, sales and other milestone payments. In addition, the agreement has a double-digit tiered royalty payment scheme that incentivizes a strong collaborative partnership.
Shares of Athenex Inc. fell 19% in morning trading. The company said it plans to share positive results for its experimental combination treatment for metastatic breast cancer at the San Antonio Breast Cancer Symposium on Friday afternoon. The Phase 3 trial tested oral paclitaxel with encequidar, an inhibitor that aims to make chemotherapies more effective. It found a stronger response rate and higher median overall survival in that combination compared to infused paclitaxel. Earlier this month SunTrust Robinson Humphrey analysts predicted $570 million in peak sales following a 2020 filing with the Food and Drug Administration. Shares of Athenex are up 33% year-to-date, compared to the S&P 500 , which has gained 26%.
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential misconduct at Athenex, Inc. ("Athenex" or the "Company") (NASDAQ:ATNX).
First oral taxane to demonstrate superior response rate and overall survival compared to IV paclitaxel in a Phase III clinical trial Data to be presented today in an oral.
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced the details for its upcoming event for the investment community, that will follow its oral presentation at the 2019 San Antonio Breast Cancer Symposium (SABCS). The event will feature presentations by Clinical Experts, who will present and review the results from the scientific session earlier that day at SABCS entitled “Oral Paclitaxel with Encequidar: The first orally administered paclitaxel shown to be superior to IV paclitaxel on confirmed response and survival with less neuropathy: a Phase III clinical study in metastatic breast cancer.” Members of Athenex’s management team will also be present to discuss the results.
Somak Chattopadhyay founded Armory Square Ventures in 2013 when the idea of a growing innovation economy in Central and Western New York was more of a theory than a working model.
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced that it has directly entered into an agreement for the sale of its common stock in a private placement with a group of institutional investors. The lead investor in the private placement is Kingdon Capital Management, LLC. The transaction is expected to result in gross proceeds to Athenex of approximately $60 million, before deducting offering expenses.
Abstract selected for the SABCS press programOral presentation of Oral Paclitaxel and encequidar Phase III results on December 13Company to host a Key Opinion Leader webcast.
Athenex (ATNX) delivered earnings and revenue surprises of 2.17% and 21.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Oral presentation of Phase III Oral Paclitaxel data at the San Antonio Breast Cancer Symposium NDA submissions for Oral Paclitaxel and tirbanibulin ointment are on track $19.2.
Athenex (ATNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BUFFALO, N.Y., Oct. 30, 2019 -- Athenex, Inc. (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel.
Athenex, Inc. (ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced a progress update from partner Almirall on tirbanibulin ointment (also known as ALM14789, formerly known as KX-01 or KX2-391) for the treatment of actinic keratosis (AK).
Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]